The PEECH Trial
The PEECH trial stand for Prospective Evaluation of ECP in Congestive Heart Failure Trial. The results of this study were presented at the 49th Scientific Sessions of the American College of Cardiology in March 2000 and the Heart Failure Society of America’s Annual Meeting in September 2000. The July/August 2002 issue of Congestive Heart Failure published a report of this study which concluded that ECP therapy increased functional capacity of the patients, was beneficial to left ventricular function and portended to be a useful adjunct to current medical therapy in heart failure patients.
That same summer, the FDA approved an IDE supplement to proceed with a pivotal study to demonstrate the efficacy of ECP therapy in the most prevalent types of heart failure patients. This study, known as the PEECH (Prospective Evaluation of ECP in Congestive Heart Failure) Trial, began patient enrollment in March 2001. PEECH involves an impressive blend of 29 academic and community–based centers, including the Cleveland Clinic, Mayo Clinic, Scripps Clinic, Thomas Jefferson University Hospital, University of North Carolina at Chapel Hill, Minnesota Heart Failure Consortium, Advocate Christ Hospital, The Lindner Center of Cincinnati, Hull Royal Infirmary (UK), University of California at San Diego Medical Center, University of Pittsburgh Medical Center and Cardiovascular Research Institute, Inc.